Perspectum

Perspectum Innovating medical imaging in Oxford - where tradition meets technology. AI-driven, patient-focused, advancing healthcare.

Perspectum is a medical diagnostics company, and developer of LiverMultiScan, a non-invasive MRI based test for liver disease. Follow the link to our website to discover more about advanced liver visualisation

We hope to use this page to keep in touch with people interested in us, as well as the wider liver community.

Perspectum is a partner of IMPACT-MED, a 60-month, €23M EU-funded initiative bringing together leading institutions acro...
22/05/2026

Perspectum is a partner of IMPACT-MED, a 60-month, €23M EU-funded initiative bringing together leading institutions across the world to advance integrated, digitally driven cardiometabolic care.

Our role: Perspectum will be delivering CoverScan, a multiorgan imaging suite, in the PRISM-T2D study to 400 adults affected by type 2 diabetes and obesity at Steno Diabetes Center in Denmark. CoverScan quantifies the health of six organs in a single, non-contrast MRI scan, and consolidates multimorbidity assessment into a unified report. Working alongside Siemens Healthineers and Aalborg University, Perspectum will combine advanced imaging, blood biomarkers, patient-reported outcomes, and AI-based risk prediction to deliver coordinated and personalised care to patients with cardiometabolic disease.

Why it matters: Cardiometabolic diseases are among the leading causes of mortality and hospitalisation in Europe, and patients still face fragmented care. Through PRISM-T2D, we will demonstrate how CoverScan can integrate care, improve patient engagement, and enhance clinical decision-making.

We were thrilled to join Oxfordshire's life sciences leaders at the House of Lords on Monday for the Innovation Showcase...
21/05/2026

We were thrilled to join Oxfordshire's life sciences leaders at the House of Lords on Monday for the Innovation Showcase, hosted by Advanced Oxford.

Rexford Newbould spoke on the panel about how the sector closes its skills gap, focusing on the structural barriers that quietly keep promising people out:

"If you can't independently support yourself, you effectively are unable to go in for these programmes. It becomes a reverse means-tested benefit."

At Perspectum we have tried to act on that belief. Paid internships, vocational training programmes, and ongoing investment in our team's development are part of how we grow talent rather than only hire it. The long-term backing we have received as a company is what makes that possible, and more of our sector could do the same.

Thank you to Advanced Oxford and Baroness Nicola Blackwood of North Oxford for convening the conversation, and to the fellow innovators featured alongside us in the showcase brochure.

We have structured pathways for MASLD and MASH. But from the conversations happening across the field, an important ques...
19/05/2026

We have structured pathways for MASLD and MASH. But from the conversations happening across the field, an important question continues to emerge:

Are current pathways giving clinicians the information they need to act early?

At the American Association of Clinical Endocrinology MASLD & MASH Care Strategic Roundtable, there was strong alignment around fibrosis-based approaches to identify patients at risk of advanced disease. These frameworks are clear, scalable, and an important step forward for broader identification.

At the same time, many of the discussions reflected ongoing challenges in clinical practice.

Even within high-risk cardiometabolic populations, patients are still not always consistently identified or worked up. And when they are, fibrosis often remains the primary lens for decision-making. While fibrosis is critical for understanding accumulated damage, there was significant discussion around whether clinicians also need tools that provide insight into current disease activity and progression.

As earlier intervention becomes a larger focus across the field, that distinction is becoming increasingly important. Questions around how to assess response, interpret discordant results, and make confident decisions earlier in the patient journey continue to surface.

One of the key themes discussed was that many existing tools were originally developed for later-stage hepatology settings, while the clinical questions arising in endocrinology and primary care are often different, focused not only on the extent of liver damage, but also on whether disease is active, progressing, or responding to intervention.

At Perspectum, these discussions closely reflect the areas where we are continuing to focus our innovation and evidence generation efforts: helping support earlier identification, deeper disease characterization, and more informed clinical decision-making.

Grateful to be part of conversations that continue to challenge assumptions and shape how MASLD and MASH care evolves.

For patients with suspected or known biliary disease, understanding what is happening within the biliary tree can be com...
15/05/2026

For patients with suspected or known biliary disease, understanding what is happening within the biliary tree can be complex, yet critical for guiding next steps. MRCP+ reports are designed to translate qualitative MRCP imaging into clear, structured insights without losing the underlying clinical depth.

The report provides a comprehensive assessment of the biliary system, including metrics such as duct dilatation, strictures, and anatomical variations. By quantifying these features, MRCP+ can enable a more objective evaluation of biliary health, supporting earlier detection and informed clinical decision-making. Each report includes visualisations and reference ranges to aid interpretation, making it practical for both specialists and referring clinicians.

By moving beyond qualitative assessment, MRCP+ supports a more standardised and reproducible approach to evaluating biliary disease, helping clinicians monitor progression and tailor management strategies over time.

Unlock access to see MRCP+ reports and case study: https://t8glx.share.hsforms.com/2Flbj77FUTdCMecx6Q3DubQ

👉 Learn more about how MRCP+ delivers quantitative insight into biliary health:

https://www.perspectum.com/products/mrcp/

Obesity-related HFpEF is often managed as a cardiac condition.But in practice, it rarely behaves like one.Patients prese...
08/05/2026

Obesity-related HFpEF is often managed as a cardiac condition.

But in practice, it rarely behaves like one.

Patients present with high symptom burden, multiple comorbidities and complex trajectories that are not fully explained by cardiac findings alone.

This work reframes HFpEF as a multiorgan condition, where the heart, liver, kidneys, adipose tissue and wider metabolic dysfunction all contribute to disease burden and treatment response.

For clinicians

This shifts what “improvement” looks like. It is not just cardiac structure or function, but changes across the whole system.

For patients

This helps provide a more complete understanding of what is driving their symptoms, better alignment between how they feel and what is being measured, and supports a more holistic approach to care.

If the disease is multiorgan, assessment may need to be as well.
Read the full paper: https://link.springer.com/article/10.1007/s10741-026-10629-z

MRCP+ is a non-invasive, quantitative MRI solution providing accurate 3D visualisation alongside precise quantitative as...
30/04/2026

MRCP+ is a non-invasive, quantitative MRI solution providing accurate 3D visualisation alongside precise quantitative assessment of the biliary tree and pancreatic duct, supporting physicians in the diagnosis and monitoring of pancreatobiliary disease.

Designed to support clinical decision-making, MRCP+ offers:

• Safe and non-invasive assessment
A quick, non-contrast MRI scan that enables comprehensive evaluation of the biliary system without invasive procedures

• Early identification
Quantitative metrics that support detection of biliary abnormalities, including strictures and dilatations, at an earlier stage

• Reliable monitoring
Enables longitudinal assessment with reproducible, repeatable measurements to track disease progression and response to intervention

• Prognostic insight
Objective ductal metrics that support risk assessment and inform management decisions

• Patient-friendly reporting
Clear, structured reports with enhanced 3D visualisations to improve clinical communication and patient understanding

Monitoring meaningful change in biliary disease can be complex. By providing quantitative metrics such as biliary tree volume, duct counts, stricture and dilatation assessment, and maximum common bile duct diameter, MRCP+ delivers objective data to complement visual interpretation and support confident decision-making.

Explore MRCP+ further and request a demo:
https://www.perspectum.com/our-products/mrcp

At American Association of Clinical Endocrinology 2026, one message came through clearly: metabolic care is moving earli...
28/04/2026

At American Association of Clinical Endocrinology 2026, one message came through clearly: metabolic care is moving earlier.

For many endocrinologists, the challenge isn’t just managing MASLD, it’s identifying risk before patients progress.

Across conversations, there was growing alignment around a more proactive approach:
non-invasive, quantitative tools that can detect, stratify, and monitor disease earlier in the pathway.

MRI-derived biomarkers such as cT1 and PDFF are increasingly being used to support:
• earlier identification of patients at risk
• more confident risk stratification
• longitudinal monitoring of clinically meaningful change

This is more than an imaging trend. It reflects a shift toward data-driven, preventative care, especially important as MASLD remains underdiagnosed despite its high prevalence and links to metabolic disease.

At Perspectum, we’re focused on enabling this transition with quantitative MRI solutions designed to integrate into clinical workflows and support better-informed decisions over time.

If we didn’t connect at AACE and you’re exploring how quantitative MRI could support your clinical practice or research:

Learn more: https://perspectum.com/
Connect with our team: https://t8glx.share.hsforms.com/2pZ-uQnvBQ562gUAkYToz9Q

Live from American Association of Clinical Endocrinology 2026Great to be on the ground connecting with clinicians and pa...
22/04/2026

Live from American Association of Clinical Endocrinology 2026

Great to be on the ground connecting with clinicians and partners across the endocrinology community, discussing how the understanding of metabolic disease continues to evolve.

At this year, we’re sharing new data on:

• Multi-organ inflammation in type 2 diabetes
• Imaging-driven risk stratification in obesity
• Scalable body composition assessment linked to clinical outcomes

If you’re attending, come and speak with the team at Booth #417 to learn more about how imaging biomarkers are supporting a more complete, quantitative assessment of metabolic health.

Obesity-related HFpEF is commonly viewed through a cardiac lens. But could expanding that view improve how we understand...
21/04/2026

Obesity-related HFpEF is commonly viewed through a cardiac lens. But could expanding that view improve how we understand and manage the condition?

Our latest review explores the condition as a multiorgan, cardio–renal–hepatic–metabolic (CRHM) syndrome, where obesity related HFpEF is promoted through metabolic dysfunction, systemic inflammation and ectopic adiposity among other factors.

By bringing together emerging evidence on incretin-based therapies and advanced imaging endpoints, the paper highlights a shift:

🔵 From single-organ thinking to integrated, system-level understanding
🔵 From indirect markers to imaging-based insights into organ health
🔵 From static assessment to tracking disease across organs over time

This perspective matters. Cardiometabolic disease does not develop in isolation, and neither should the tools we use to understand and monitor it.

Read the full paper: https://link.springer.com/article/10.1007/s10741-026-10629-z

Solid Habits, Strong Liver.This World Liver Day focuses on the everyday choices that support liver health, nutrition, mo...
19/04/2026

Solid Habits, Strong Liver.

This World Liver Day focuses on the everyday choices that support liver health, nutrition, movement, and routine checks.

But there is a challenge.

Liver disease often develops silently, with many people feeling well until it has progressed.

Habits matter. Understanding the impact of you habits is what makes change possible

LiverMultiScan provides non-invasive insight into liver health, helping to:

Quantify liver fat, disease activity, and iron
Identify signs of liver disease before symptoms appear
Monitor changes over time
Because strenghting your liver health is not just about what you do, it’s about what you can see and track.

This World Liver Day, consider not only the habits that support liver health, but how you understand their impact.

Learn more: https://perspectum.com/

Address

Gemini One 5520 John Smith Drive
Oxford
OX42LL

Opening Hours

Monday 9am - 5pm
Tuesday 9am - 5pm
Wednesday 9am - 5pm
Thursday 9am - 5pm
Friday 9am - 5pm

Telephone

+44 (0)1865 655343

Website

Alerts

Be the first to know and let us send you an email when Perspectum posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Perspectum:

Shortcuts

Share

Category